A new compound drug could be effective in treating hepatitis C by attacking RNA that allows the virus to gain traction in a patient's body. The drug, miravirsen, targets the body's microRNA-122, preventing viral replication, according to findings published in the New England Journal of Medicine. The treatment could potentially also treat other serious diseases, including cancer. "This is really a revolution in science and it's now beginning to be translated into advances that control disease," said Phillip Sharp, an MIT molecular biologist who won a 1993 Nobel Prize for work on RNA.
Drug treats hepatitis C by targeting body's RNA
SmartBrief Job Listings for Education
|Instructional Designer, ESL||
Imagine Learning, Inc.
|Sr. Product Manager - Professional Development||
|Sr. Product Manager - Formative Assessment Product Line||
|Multiple Locations, SL_Multiple Locations|
|Product Support Specialist||
Insight Education Group